Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of CC-486 Plus Nivolumab in Patients With Hodgkin Lymphoma Refractory to PD-1 Therapy

NCT05162976 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT05162976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05162976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of CC-486 Plus Nivolumab in Patients With Hodgkin Lymphoma Refractory to PD-1 Therapy
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
January 3, 2022
Completion date
April 27, 2027
Enrollment
33 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent classic hodgkin lymphoma, refractory classic hodgkin lymphoma